Zhitong Finance APP News, Yunnan Baiyao (000538.SZ) announced that on June 27, 2024, the company will hold the 10th Board of Directors meeting to deliberate the proposal for introducing the KA-1641 project. The company agreed to introduce the relevant patent of the KA-1641 antibody drug from Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd. and conduct research and development, production and commercial activities on the target products globally. The down payment for this transaction is 6 million yuan, and the R&D and registration milestone payment is 32 million yuan.

It is reported that KA-1641 is currently in the preclinical production process research and development stage, with the first indication for tumor cachexia. The introduction of this antibody drug will help enrich the innovation drug research and development pipeline of Yunnan Baiyao and produce synergies in the tumor field with nuclear medicine and other products. It is beneficial to bridge the research and development chain from preclinical research and development to clinical research of antibody drugs, and it can also accumulate experience and lay a foundation for subsequent self-research or introduction of other innovative drugs.

The company stated that innovative drugs are one of the important layout areas of the company's research and development plan. The introduction of the KA-1641 project has important strategic significance for the company to build a perfect innovative drug research and development system and product layout. KA-1641 can strengthen the company's competitiveness in the tumor innovative drug field together with the existing nuclear medicine product line, which is in line with the strategic direction of innovative drug layout. With this project as an opportunity, it can help bridge the research and development chain from preclinical research and development to clinical research of antibody drugs, which is conducive to subsequent self-research or introduction of other innovative drugs. The competition pattern of this antibody drug is good, and it can form a characteristic tumor-related product matrix together with nuclear medicine diagnosis and treatment products in the future, forming synergy development, and fully utilizing the future construction of in-hospital channels for tumors.